Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Medical - Diagnostics & Research

Healthcare
$1.59 +2.44%

+$0.13 today

Market cap
$52.08M
Beta
1.79
P/E (TTM)
-3.9
EPS (TTM)
-$1.39
52W Low $2.33High $8.51

Volume 0.64M

Average 0.38M

IMDX EBITDA Margin

EBITDA as a percentage of revenue.

Insight Molecular Diagnostics Inc.NASDAQ: IMDX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -11362.5%

EBITDA Margin was -11362.5% in Q1 FY2026, down 11074.8 pp from a year earlier. On a trailing-twelve-month basis it was -2329.5%, down 862.2 pp year over year. Over 3 fiscal years it widened by 207.6 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -1611.6% for the fiscal year ending Dec 2026, down from -1181.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-11362.5%-9398.8 pp QoQ
Last fiscal yearDec 2025
-1181.7%+1955.8 pp YoY
LTMMar 2026
-2329.5%-862.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-11074.8 pp-693.4 pp+10381.4 pp
1 year+1955.8 pp-429.9 pp-2385.7 pp
3 years+207.6 pp+1103.3 pp+895.7 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1181.7%
Year-over-year change
+1955.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IMDX compares with its peers on the latest reported figures

  • IMDX's LTM Mar 2026 EBITDA Margin of -2329.5% is the 7th highest of the 9 companies compared; the peer median is -313.9%.
  • Its year-over-year change of -862.2 pp is the 7th highest of 8, against a peer median of +50.4 pp.
  • Over three fiscal years its change of +207.6 pp compares with a peer median of -178.5 pp.
IMDX Competitors Peer median
EBITDA Margin for IMDX and competitors
Company Period LTM level YoY 3-year change
CDXSCodexis, Inc.LTM Mar 2026-28.2% +91.2 pp-29.1 pp
OABIOmniAb, Inc.LTM Mar 2026-117.0% +50.4 pp-225.4 pp
IVVDInvivyd, Inc.LTM Mar 2026-135.5% +244.4 pp—
CCCCC4 Therapeutics, Inc.LTM Mar 2026-287.9% -44.6 pp+113.4 pp
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-339.9% -229.0 pp-131.5 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-455.3% +1345.3 pp—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-2329.5% -862.2 pp+207.6 pp
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-3439.7% —-2679.5 pp
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026-8872.8% -9159.7 pp-2521.0 pp
PEPGPepGen Inc.FY2025— ——
Peer median (excluding IMDX) -313.9%+50.4 pp-178.5 pp

Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.2M958K1.5M1.88M4.06M
Cost of Revenue778K976K1.09M1.14M3.87M
Gross Profit1.42M(18K)413K740K190K
Gross Margin64.6%-1.9%27.5%39.3%4.7%
Research & Development5.04M7.3M9.29M9.84M15.9M
Selling, General & Admin20.39M21.53M13.29M13.79M16.98M
Operating Expenses55.15M17.98M25.55M61.78M30.77M
Depreciation & Amortization4.21M5.22M1.68M1.56M2.2M
EBITDA(48.46M)(13.31M)(23.12M)(59.02M)(47.92M)
EBITDA Margin-2204.6%-1389.2%-1538.5%-3137.4%-1181.7%
Operating Income(53.73M)(18M)(25.14M)(61.04M)(30.58M)
Operating Margin-2444.3%-1878.6%-1672.4%-3245.1%-754.1%
Interest Income00000
Interest Expense209K83K52K84K109K
Other Income / Expenses854K(615K)281K378K(19.64M)
Income Before Tax(52.87M)(18.61M)(24.86M)(60.66M)(50.22M)
Pre-Tax Margin-2405.4%-1942.8%-1653.7%-3225.0%-1238.5%
Income Tax Expense(9.26M)0000
Net Income(64.1M)(72.9M)(27.78M)(60.66M)(50.22M)
Net Margin-2916.2%-7609.8%-1848.4%-3225.0%-1238.5%
EPS (Basic)(14.40)(20.00)(3.75)(4.66)(1.65)
EPS (Diluted)(14.40)(20.00)(3.75)(4.66)(1.65)
Weighted Avg Shares4.45M5.54M7.65M13.07M30.48M
Weighted Avg Shares (Diluted)4.45M5.54M7.65M13.07M30.48M

Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Intrinsic Alpha fair value

Locked

Current Price

$1.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.